Retatrutide

Discovery and Design Rationale

Retatrutide (development code LY3437943, often nicknamed "Triple G") is a synthetic peptide agonist engineered by Eli Lilly to simultaneously activate three receptors: GLP-1, GIP, and glucagon. It extends the multi-agonist thesis proven by tirzepatide by adding a third incretin-family receptor, with the design hypothesis that glucagon receptor activation contributes to energy expenditure and hepatic lipid mobilization in a way that GLP-1 and GIP agonism alone cannot match.

Structurally, retatrutide is a lipidated 39-residue peptide with a fatty-acid side chain supporting once-weekly subcutaneous dosing. The receptor affinity profile is tuned so that glucagon agonism drives thermogenesis and lipolysis without producing the hyperglycemia that glucagon receptor activation would cause in isolation — the concurrent GLP-1 insulinotropic effect offsets it.

Mechanism of Action

Adding the glucagon receptor to the dual incretin substrate produces a mechanistically distinct agent:

• Hepatic fat mobilization. Glucagon receptor activation in the liver drives increased fatty-acid oxidation, which may explain the unusually large reductions in hepatic steatosis reported in Phase 2.
• Increased energy expenditure. Small rises in resting metabolic rate have been documented, consistent with glucagon's thermogenic role.
• GLP-1 and GIP effects preserved. Insulinotropic response, glucagon suppression in postprandial states, delayed gastric emptying, and hypothalamic appetite suppression operate as in the dual agonist.

Clinical Evidence

Phase 2 data published in The New England Journal of Medicine in June 2023 showed mean weight loss of 24.2% at 48 weeks on the 12 mg dose in adults with obesity, the largest magnitude reported for any GLP-1-class investigational agent at that stage. Parallel Phase 2 work in type 2 diabetes reported HbA1c reductions of up to 2.0 percentage points and meaningful improvements in hepatic fat fraction on MRI.

The Phase 3 program, named TRIUMPH, began enrolling in late 2023 across multiple arms: TRIUMPH-1 through TRIUMPH-4 cover obesity with and without type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and cardiovascular outcomes in established disease. Top-line TRIUMPH readouts are expected through 2026–2027, with potential first FDA approval in 2026 if filings proceed on schedule.

Where It Fits in the Pipeline

Retatrutide is the most advanced triple agonist, but not the only one — Boehringer Ingelheim's survodutide (dual GLP-1/glucagon) and several next-generation candidates from Altimmune and others are testing variations on the multi-receptor theme. The broader landscape also includes amylin-containing combinations such as Novo Nordisk's amycretin, which pursues a different receptor pairing entirely.

Safety Signals and Open Questions

Phase 2 tolerability was broadly consistent with the GLP-1 class — nausea, vomiting, and diarrhea dominant, concentrated in titration. Heart rate elevation of roughly 3–7 bpm was observed, slightly higher than with tirzepatide, and is an area of Phase 3 scrutiny. Whether the added glucagon agonism produces any signal for lean-mass loss, cholelithiasis, or hepatic enzyme elevation beyond the dual-agonist baseline will be established by the TRIUMPH datasets.

The Bottom Line

Retatrutide is, as of early 2026, the most promising investigational weight-loss agent in late-stage development, with Phase 2 efficacy that exceeds approved dual-agonist therapy. It is not yet approved for any indication, and the clinical and regulatory picture will sharpen substantially as TRIUMPH data emerges through 2026 and 2027. For a comparison with the currently approved agents in the class, see our 2026 head-to-head analysis.